Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2004

View Archived Issues

Opioid growth factor phase I trial in patients with advanced inoperable pancreatic carcinoma

Talaporfin reported to reduce choroidal leakage in ARMD

Biocryst reports exciting progress during past quarter

Avant Immunotherapeutics achieves notable milestones in the first quarter

Novel human anticancer vaccine elicits cellular responses

Insight into mechanism of action of AGI-1067

Laquinimod reported to delay progression of multiple sclerosis

Clinical benefits of pramlintide in the treatment of diabetes

Rasagiline improves motor fluctuations and freezing of gait in advanced PD

Promising results reported for AdPEDF.11 in choroidal neovascularization

Prous Science's LifeSci Channel posts several new exiting programs

Five series of ALK5 kinase inhibitors presented by Pfizer

AstraZeneca claims 11beta-HSD1 inhibitors for diabetes, obesity, etc.

Cyclic peptide with glucagon antagonist activity isolated from Streptomyces cultures

New cannabinoid CB1 antagonists/inverse agonists claimed by Pfizer

Pfizer patent covers p38 MAP kinase inhibitors and their therapeutic use

French researchers describe imidazoline-based glucose and lipid lowering agents

First portion of Entereg NDA submitted

Biovitrum and Symphogen enter recombinant polyclonal antibody collaboration

Visudyne launched in Japan

ARIC data support stroke predictive value of Lp-PLA2

CTA submitted for Canadian phase I trials of TAFA-93

New phase II trial for Aplidin in SCLC

Sysmex collaboration to test automated cervical cancer screening technology

Exanta completes E.U. mutual recognition procedure

SPA for phase III GVAX prostate cancer vaccine trial

IDEA-070 reduces cutaneous inflammation

HE-2000 reduces HIV load, opportunistic infections in AIDS patients

Tolevamer development advances based on study results

Recent results with tamsulosin reported at AUA annual meeting

Study shows melatonin improves nocturia

Peptimmune licenses rights to GT389-255 from Genzyme

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.